Cargando…

Human Lupus Plasma Pro-Atherogenic Effects on Cultured Macrophages Are Not Mitigated by Statin Therapy: A Mechanistic LAPS Substudy

Background and Objectives: Atherosclerotic cardiovascular disease (CVD) remains a major cause of morbidity and mortality in persons with systemic lupus erythematosus (SLE, lupus). Atherosclerosis, which involves interplay between cholesterol metabolism and cellular inflammatory pathways, is primaril...

Descripción completa

Detalles Bibliográficos
Autores principales: Reiss, Allison B., Arain, Hirra A., Kasselman, Lora J., Renna, Heather A., Zhen, Juan, Voloshyna, Iryna, DeLeon, Joshua, Carsons, Steven E., Petri, Michelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780986/
https://www.ncbi.nlm.nih.gov/pubmed/31438615
http://dx.doi.org/10.3390/medicina55090514
_version_ 1783457271755309056
author Reiss, Allison B.
Arain, Hirra A.
Kasselman, Lora J.
Renna, Heather A.
Zhen, Juan
Voloshyna, Iryna
DeLeon, Joshua
Carsons, Steven E.
Petri, Michelle
author_facet Reiss, Allison B.
Arain, Hirra A.
Kasselman, Lora J.
Renna, Heather A.
Zhen, Juan
Voloshyna, Iryna
DeLeon, Joshua
Carsons, Steven E.
Petri, Michelle
author_sort Reiss, Allison B.
collection PubMed
description Background and Objectives: Atherosclerotic cardiovascular disease (CVD) remains a major cause of morbidity and mortality in persons with systemic lupus erythematosus (SLE, lupus). Atherosclerosis, which involves interplay between cholesterol metabolism and cellular inflammatory pathways, is primarily treated with statins since statins have lipid-lowering and anti-inflammatory properties. The Lupus Atherosclerosis Prevention Study (LAPS) was designed to investigate the efficacy of statins against CVD in SLE patients. LAPS demonstrated that 2 years of atorvastatin administration did not reduce atherosclerosis progression in lupus patients. In this LAPs substudy, we use cultured macrophages to explore the atherogenic properties of plasma from LAPS subjects to explain the mechanistic rationale for the inability of statins to reduce CVD in lupus. Materials and Methods: THP-1 differentiated macrophages were treated for 18 h with 10% SLE patient plasma obtained pre- and post-atorvastatin therapy or placebo. Gene expression of the following cholesterol transport genes was measured by qRT-PCR. For efflux—ATP binding cassette transporter (ABC)A1 and ABCG1, 27-hydroxylase, peroxisome proliferator-activated receptor (PPAR)γ, and liver X receptor (LXR)α; and for influx—cluster of differentiation 36 (CD36) and scavenger receptor (ScR)A1. Results: Macrophages exposed to plasma from both statin-treated and placebo-treated groups showed a significant decrease in cholesterol efflux proteins ATP binding cassette (ABC) transporters A1 and ABCG1, an increase in 27-hydroxylase, an increase in the LDL receptor and a decrease in intracellular free cholesterol. No change in influx receptors ScRA1 and CD36, nor nuclear proteins LXRα and PPARγ was observed. Conclusions: Statins do not normalize pro-atherogenic changes induced by lupus and these changes continue to worsen over time. This study provides mechanistic insight into LAPS findings by demonstrating that statins are overall ineffective in altering the balance of cholesterol transport gene expression in human macrophages. Furthermore, our study suggests that statins as a CVD treatment may not be useful in attenuating lipid overload in the SLE environment.
format Online
Article
Text
id pubmed-6780986
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67809862019-10-30 Human Lupus Plasma Pro-Atherogenic Effects on Cultured Macrophages Are Not Mitigated by Statin Therapy: A Mechanistic LAPS Substudy Reiss, Allison B. Arain, Hirra A. Kasselman, Lora J. Renna, Heather A. Zhen, Juan Voloshyna, Iryna DeLeon, Joshua Carsons, Steven E. Petri, Michelle Medicina (Kaunas) Article Background and Objectives: Atherosclerotic cardiovascular disease (CVD) remains a major cause of morbidity and mortality in persons with systemic lupus erythematosus (SLE, lupus). Atherosclerosis, which involves interplay between cholesterol metabolism and cellular inflammatory pathways, is primarily treated with statins since statins have lipid-lowering and anti-inflammatory properties. The Lupus Atherosclerosis Prevention Study (LAPS) was designed to investigate the efficacy of statins against CVD in SLE patients. LAPS demonstrated that 2 years of atorvastatin administration did not reduce atherosclerosis progression in lupus patients. In this LAPs substudy, we use cultured macrophages to explore the atherogenic properties of plasma from LAPS subjects to explain the mechanistic rationale for the inability of statins to reduce CVD in lupus. Materials and Methods: THP-1 differentiated macrophages were treated for 18 h with 10% SLE patient plasma obtained pre- and post-atorvastatin therapy or placebo. Gene expression of the following cholesterol transport genes was measured by qRT-PCR. For efflux—ATP binding cassette transporter (ABC)A1 and ABCG1, 27-hydroxylase, peroxisome proliferator-activated receptor (PPAR)γ, and liver X receptor (LXR)α; and for influx—cluster of differentiation 36 (CD36) and scavenger receptor (ScR)A1. Results: Macrophages exposed to plasma from both statin-treated and placebo-treated groups showed a significant decrease in cholesterol efflux proteins ATP binding cassette (ABC) transporters A1 and ABCG1, an increase in 27-hydroxylase, an increase in the LDL receptor and a decrease in intracellular free cholesterol. No change in influx receptors ScRA1 and CD36, nor nuclear proteins LXRα and PPARγ was observed. Conclusions: Statins do not normalize pro-atherogenic changes induced by lupus and these changes continue to worsen over time. This study provides mechanistic insight into LAPS findings by demonstrating that statins are overall ineffective in altering the balance of cholesterol transport gene expression in human macrophages. Furthermore, our study suggests that statins as a CVD treatment may not be useful in attenuating lipid overload in the SLE environment. MDPI 2019-08-21 /pmc/articles/PMC6780986/ /pubmed/31438615 http://dx.doi.org/10.3390/medicina55090514 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Reiss, Allison B.
Arain, Hirra A.
Kasselman, Lora J.
Renna, Heather A.
Zhen, Juan
Voloshyna, Iryna
DeLeon, Joshua
Carsons, Steven E.
Petri, Michelle
Human Lupus Plasma Pro-Atherogenic Effects on Cultured Macrophages Are Not Mitigated by Statin Therapy: A Mechanistic LAPS Substudy
title Human Lupus Plasma Pro-Atherogenic Effects on Cultured Macrophages Are Not Mitigated by Statin Therapy: A Mechanistic LAPS Substudy
title_full Human Lupus Plasma Pro-Atherogenic Effects on Cultured Macrophages Are Not Mitigated by Statin Therapy: A Mechanistic LAPS Substudy
title_fullStr Human Lupus Plasma Pro-Atherogenic Effects on Cultured Macrophages Are Not Mitigated by Statin Therapy: A Mechanistic LAPS Substudy
title_full_unstemmed Human Lupus Plasma Pro-Atherogenic Effects on Cultured Macrophages Are Not Mitigated by Statin Therapy: A Mechanistic LAPS Substudy
title_short Human Lupus Plasma Pro-Atherogenic Effects on Cultured Macrophages Are Not Mitigated by Statin Therapy: A Mechanistic LAPS Substudy
title_sort human lupus plasma pro-atherogenic effects on cultured macrophages are not mitigated by statin therapy: a mechanistic laps substudy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780986/
https://www.ncbi.nlm.nih.gov/pubmed/31438615
http://dx.doi.org/10.3390/medicina55090514
work_keys_str_mv AT reissallisonb humanlupusplasmaproatherogeniceffectsonculturedmacrophagesarenotmitigatedbystatintherapyamechanisticlapssubstudy
AT arainhirraa humanlupusplasmaproatherogeniceffectsonculturedmacrophagesarenotmitigatedbystatintherapyamechanisticlapssubstudy
AT kasselmanloraj humanlupusplasmaproatherogeniceffectsonculturedmacrophagesarenotmitigatedbystatintherapyamechanisticlapssubstudy
AT rennaheathera humanlupusplasmaproatherogeniceffectsonculturedmacrophagesarenotmitigatedbystatintherapyamechanisticlapssubstudy
AT zhenjuan humanlupusplasmaproatherogeniceffectsonculturedmacrophagesarenotmitigatedbystatintherapyamechanisticlapssubstudy
AT voloshynairyna humanlupusplasmaproatherogeniceffectsonculturedmacrophagesarenotmitigatedbystatintherapyamechanisticlapssubstudy
AT deleonjoshua humanlupusplasmaproatherogeniceffectsonculturedmacrophagesarenotmitigatedbystatintherapyamechanisticlapssubstudy
AT carsonsstevene humanlupusplasmaproatherogeniceffectsonculturedmacrophagesarenotmitigatedbystatintherapyamechanisticlapssubstudy
AT petrimichelle humanlupusplasmaproatherogeniceffectsonculturedmacrophagesarenotmitigatedbystatintherapyamechanisticlapssubstudy